Elsevier

NeuroImage

Volume 33, Issue 3, 15 November 2006, Pages 834-842
NeuroImage

A PET imaging study of 5-HT1A receptors in cat brain after acute and chronic fluoxetine treatment

https://doi.org/10.1016/j.neuroimage.2006.08.012Get rights and content

Abstract

Immuno-electron microscopic and β-microprobe studies have demonstrated that the internalization of serotonin 5-HT1A autoreceptors, after acute treatment with the selective 5-HT1A receptor agonist 8-OH-DPAT or with the specific serotonin reuptake inhibitor (SSRI) fluoxetine, is associated with a marked decrease in the in vivo binding of [18F]MPPF in the nucleus raphe dorsalis (NRD) of rat. To determine whether this event might be amenable to brain imaging, the present [18F]MPPF positron emission tomographic (PET) study was carried out in anesthetized cats given or not a single dose (5 mg/kg, i.v.) or chronically treated with fluoxetine (5 mg/kg, s.c. for 21 days). Compared to control, [18F]MPPF binding potential was considerably (and visibly) decreased in the cat NRD after acute fluoxetine treatment, while it remained unchanged in other brain regions. Unexpectedly, after chronic fluoxetine treatment, [18F]MPPF binding potential was not affected in any brain region. In parallel immuno-electron microscopic experiments carried out in rat, the density of 5-HT1A autoreceptors on the plasma membrane of NRD dendrites was comparable to control after chronic fluoxetine treatment. If the decrease in [18F]MPPF binding at the onset of SSRI treatment was detectable by PET imaging, it could potentially serve as a biological index of efficacy.

Introduction

Serotonin 1A receptors (5-HT1AR) play a key role in the antidepressant effects of selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRIs). In brain 5-HT nuclei, such as the nucleus raphe dorsalis (NRD), these receptors are located on the plasma membrane of 5-HT cell bodies and dendrites (Sotelo et al., 1990, Kia et al., 1996, Riad et al., 2000) and act as autoreceptors that negatively regulate the firing and hence release of 5-HT by these neurons (Sprouse and Aghajanian, 1987, Hjorth and Magnusson, 1988, Hutson et al., 1989, Sharp et al., 1989). Electrophysiological and microdialysis studies in rodents have indicated that, at the onset of SSRI treatment, the resulting increase in extracellular 5-HT (Bel and Artigas, 1992, Rutter and Auerbach, 1993, Kreiss and Lucki, 1995, Hervás and Artigas, 1998) activates 5-HT1A autoreceptors and therefore reduces 5-HT neuron firing and release (Adell and Artigas, 1991, Hjorth and Auerback, 1994, Rutter et al., 1995). However, 5-HT1A autoreceptors are subject to a desensitization (Kennett et al., 1987, Beer et al., 1990, Seth et al., 1997), which is transient after acute treatment with an agonist or SSRI (Casanovas et al., 1997, Le Poul et al., 2000), but allows for a return to initial firing rate and release of 5-HT from neurons, without negative feedback, after 2 or 3 weeks of SSRI treatment (Blier et al., 1984, Hamon et al., 1988, Jolas et al., 1994, Le Poul et al., 1995, Le Poul et al., 2000, Czachura and Rasmussen, 2000). Because this desensitization of 5-HT1A autoreceptors must take place for 5-HT neurotransmission to increase under SSRI treatment, it may be viewed as a prerequisite to the therapeutic efficacy of these drugs as antidepressants (for reviews, see Blier and de Montigny, 1994, Piñeyro and Blier, 1999).

Using quantitative electron microscopic immunocytochemistry with a highly specific antibody against 5-HT1AR (El Mestikawy et al., 1990), we have previously shown in rat that acute treatment with the selective 5-HT1AR agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT), or with the SSRI fluoxetine (Prozac®), induces an internalization of more than 35% of plasma membrane 5-HT1A autoreceptors in the NRD (Riad et al., 2001, Riad et al., 2004). This internalization may account for the early desensitization of 5-HT1A autoreceptors after acute treatment, and it is not observed in pyramidal and granule cells of the hippocampus, the 5-HT1AR of which (heteroreceptors) do not desensitize (Piñeyro et al., 1994, Haddjeri et al., 1998). In parallel experiments with β-sensitive microprobes implanted next to the NRD and into hippocampus, we have also demonstrated that acute treatment with 8-OH-DPAT or with fluoxetine entails equivalent decreases of the specific in vivo binding of the 5-HT1AR PET radioligand [18F]MPPF in the NRD, without any concomitant change in hippocampus (Riad et al., 2004, Zimmer et al., 2004). These decreases could be imputed to the internalization of 5-HT1A autoreceptors since the local availability of [18F]MPPF in vivo, as measured by microdialysis (Zimmer et al., 2004), as well as its in vitro binding in NRD and hippocampus, as measured by autoradiography in tissue sections, did not differ between control and fluoxetine-treated rats (Riad et al., 2004).

Because the decreased [18F]MPPF binding in NRD, associated with the internalization of 5-HT1A autoreceptors, might provide an index of desensitization of these receptors at the onset of antidepressant treatment, we undertook the present brain imaging study to examine the possibility of detecting and measuring this event with PET, following acute and chronic treatment with the SSRI fluoxetine. Knowing that the distribution and binding properties of 5-HT1A autoreceptors were comparable in feline and rodent NRD (Charnay et al., 1997, Ginovart et al., 2000, Aznavour et al., 2006), the experiments were carried out in cat in order to avoid limitations in imaging resolution that might compromise the acquisition of microPET data on rat NRD. It turned out, however, that reliable interpretation of the results after chronic treatment required information from a concomitant immunocytochemical electron microscopic study, which had to be carried out in rat due to the limited cross-species reactivity of available 5-HT1A receptor antibodies. Part of the latter findings was therefore included as preliminary data in the present report.

Section snippets

Acute and chronic fluoxetine treatment (cat)

These studies were performed in accordance with French (87-848, Ministère de l’Agriculture et de la Forêt) and European Economic Community (86-60, EEC) guidelines for care of laboratory animals and were approved by the regional ethical animal use committee. Three adult male cats, weighing 3–4 kg, were obtained from Charles River Laboratories (L’Arbresle, France). Each animal was subjected to five [18F]MPPF scanning sessions, two for determining baseline values, two after acute fluoxetine

PET imaging and measurement of [18F]MPPF binding

In keeping with earlier demonstrations (Ginovart et al., 2000, Aznavour et al., 2006), there was a strong accumulation of radioactivity in several regions of cat brain after the intravenous injection of [18F]MPPF (Fig. 1, Fig. 2). Above background labeling was visualized in infralimbic cortex (Figs. 1A–C), cingulate cortex (Figs. 1D–L), lateral septum (Figs. 1D–F), hippocampus (Fig. 1, Fig. 2) and NRD (Fig. 1, Fig. 2). Co-registration of PET and MRI images confirmed the anatomical localization

Methodological considerations

The present PET study demonstrated a significant decrease in [18F]MPPF BP in cat NRD following acute but not chronic fluoxetine treatment. The realignment of PET and MRI images in each cat was crucial in obtaining these data and ensuring the reliability of the measurements. Indeed, a shift in the spatial orientation of the cat’s head could have altered the results, in such a small brain region. In view of the small size of the cat NRD and the resolution of the PET camera, the BP values of this

Acknowledgments

N. Aznavour is a recipient of a postdoctoral fellowship from the Swiss National Science Foundation. The authors are grateful to V. Gualda and M. Malleval for their technical support in the PET experiments and D. Sappey-Marinier for his help with MRI. This research was supported by the French program CNRS-CEA “Imagerie du Petit Animal” to L.Z. and grant NRF 3544 from the Canadian Institutes for Health Research to L.D.

References (67)

  • I. Hervás et al.

    Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors

    Eur. J. Pharmacol.

    (1998)
  • S. Hjorth et al.

    Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors

    Eur. J. Pharmacol.

    (1994)
  • P.H. Hutson et al.

    Hippocampal 5-HT synthesis and release in vivo is decreased by infusion of 8-OH-DPAT into the nucleus raphe dorsalis

    Neurosci. Lett.

    (1989)
  • X. Khawaja

    Quantitative autoradiographic characterisation of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist

    Brain Res.

    (1995)
  • G.A. Kennett et al.

    Single administration of 5-HT1A agonists decreases 5-HT1A presynaptic, but not postsynaptic receptor-mediated responses: relationship to antidepressant-like action

    Eur. J. Pharmacol.

    (1987)
  • D. Le Bars et al.

    High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635

    Nucl. Med. Biol.

    (1998)
  • E. Le Poul et al.

    Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine

    Neuropharmacology

    (2000)
  • R.V. Parsey et al.

    Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study

    Biol. Psychiatry

    (2006)
  • V.W. Pike et al.

    Radioligands for the study of brain 5-HT1A receptors in vivo

  • C. Shen et al.

    Repeated treatment with antidepressants differentially alters 5-HT1A agonist-stimulated [35S]GTP gamma S binding in rat brain regions

    Neuropharmacology

    (2002)
  • L. Zimmer et al.

    Toward brain imaging of serotonin 5-HT1A autoreceptor internalization

    NeuroImage

    (2004)
  • A. Adell et al.

    Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex

    Naunyn-Schmiedeberg's Arch. Pharmacol.

    (1991)
  • M. Beer et al.

    A single dose of 8-OH-DPAT reduces raphe binding of [3H]8-OH-DPAT and increases the effect of raphe stimulation on 5-HT metabolism

    Eur. J. Pharmacol.

    (1990)
  • N. Bel et al.

    Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei

    Synapse

    (1993)
  • P. Blier et al.

    Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: single-cell studies in the rat

    Psychopharmacology

    (1984)
  • G. Brix et al.

    Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association

    J. Nucl. Med.

    (1997)
  • J.M. Casanovas et al.

    The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain

    Br. J. Pharmacol.

    (1997)
  • M.E. Castro et al.

    Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT1A receptors in rat brain

    Neuropharmacology

    (2003)
  • Y. Charnay et al.

    Mapping of 5-HT1A receptor binding sites in the feline brain: a quantitative autoradiographic study using [3H]8-OH-DPAT

    Biog. Amines

    (1997)
  • N. Costes et al.

    Modeling [18F]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection

    J. Cereb. Blood Flow Metab.

    (2002)
  • N. Costes et al.

    A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging

    J. Nucl. Med.

    (2005)
  • J.F. Czachura et al.

    Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat

    Naunyn-Schmiedeberg's Arch. Pharmacol.

    (2000)
  • P.H. Elsinga et al.

    PET studies on P glycoprotein function in the blood–brain barrier: how it affects uptake and binding of drugs within the CNS

    Curr. Pharm. Des.

    (2004)
  • Cited by (42)

    • Chronic fluoxetine rescues changes in plasma membrane density of 5-HT1A autoreceptors and serotonin transporters in the olfactory bulbectomy rodent model of depression

      2017, Neuroscience
      Citation Excerpt :

      Activation of somatodendritic 5-HT1A auto-receptors by locally released 5-HT inhibits firing of 5-HT neurons, thereby reducing 5-HT actions throughout the brain (Blier and de Montigny, 1987; Sprouse and Aghajanian, 1987; Hutson et al., 1989; Sharp et al., 1989; Adell et al., 2002). In animal studies of antidepressant treatment with selective serotonin reuptake inhibitors, the firing rate of 5-HT neurons is reduced at initiation of treatment and recovers over weeks, corresponding with the time course of 5-HT1A auto-receptor desensitization and/or internalization (Li et al., 1996; Le Poul et al., 1997; Czachura and Rasmussen, 2000; Aznavour et al., 2006; Riad et al., 2008). Because 5-HT1A hetero-receptors on 5-HT neuron projection targets do not desensitize or internalize (Kennett et al., 1987; Beer et al., 1990; Haddjeri et al., 1998; Piñeyro and Blier, 1999; Le Poul et al., 2000; Riad et al., 2001, 2004, 2008), the net effect of 5-HT1A auto-receptor internalization is enhancement of serotonergic transmission.

    • Test-retest reliability of task-related pharmacological MRI with a single-dose oral citalopram challenge

      2013, NeuroImage
      Citation Excerpt :

      In this way, the neural activity related to the 5-HT response can be visualized (for a recent review on this topic, please refer to Anderson et al., 2008). In comparison with other imaging techniques, such as positron emission tomography (PET) (Aznavour et al., 2006) and single photon emission computed tomography (SPECT) (Hwang et al., 2007), fMRI is pre-eminently suitable for measuring (changes in) neural activity and offers both excellent spatial as well as good temporal resolution. It is also less invasive due to the lack of involved radiation exposure.

    View all citing articles on Scopus
    View full text